YPT-01 is under clinical development by Felix Biotechnology and currently in Phase II for Pseudomonas aeruginosa Infections. According to GlobalData, Phase II drugs for Pseudomonas aeruginosa Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the YPT-01 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

YPT-01 overview

YPT-01 is under investigation for the treatment of chronic Pseudomonas aeruginosa airway infections associated with cystic fibrosis. The therapy comprises of inhaled bacteriophage (phage) therapy.

Felix Biotechnology overview

Felix Biotechnology, is a biotechnology company that focused on accelerating the deployment of novel biotherapeutics targeting urgent microbial challenges in human health and beyond. The company is headquartered in United States.

For a complete picture of YPT-01’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.